# **Functional Group Selective Derivatization and Gas-Phase Fragmentation Reactions of Plasmalogen Glycerophospholipids**

Cassie J. Fhaner,<sup>1</sup> Sichang Liu,<sup>1</sup> Xiao Zhou,<sup>1</sup> and Gavin E. Reid<sup>\*,1,2</sup>

<sup>1</sup>*Department of Chemistry, Michigan State University, East Lansing, Michigan, USA* <sup>2</sup>*Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan, USA*

A reaction strategy involving functional group selective modification of the *O*-alkenyl-ether double bond within plasmenyl ether containing lipids using iodine and methanol, in conjunction with functional group selective derivatization of amine-containing lipids using a novel <sup>13</sup>C<sub>1</sub>-S,S'-dimethylthiobutanoylhydroxysuccinimide ester (<sup>13</sup>C<sub>1</sub>-DMBNHS) reagent, is shown to improve the capabilities of 'shotgun' high resolution/accurate mass spectrometry for comprehensive lipidome analysis. Importantly, the characteristic mass shifts introduced as a result of these derivatization reactions enables the resolution and unambiguous identification of isobaric mass plasmenyl- and plasmanyl-ether containing lipid species from within crude complex lipid extracts, without need for chromatographic fractionation or additional lipid extraction steps prior to analysis. Additionally, the positive ionization mode tandem mass spectrometry fragmentation behavior of the derivatized plasmenyl ether containing glycerophosphocholine and glycerophosphoethanolamine lipids are shown to yield abundant characteristic product ions that directly enable the assignment of their molecular lipid identities.

*Keywords*: plasmalogen lipid, ether lipid, aminophospholipid, iodine/methanol derivatization, sulfonium ion derivatization, high resolution ESI-MS, CID-MS/MS

(Received October 18, 2012; Accepted November 15, 2012)

# **INTRODUCTION**

Plasmenyl (*i.e.*, 1-*O*-alkenyl-ether or plasmalogen) and plasmanyl (*i.e.*, 1-*O*-alkyl-ether) linked glycerophospholipids are known to play a role in the regulation of several cellular membrane functions such as fusion, fission and fluidity, regulating the activity of membrane-bound proteins, and protection against oxidative degradation.<sup>1-5)</sup> Furthermore, aberrant levels of these lipids within cellular membranes, particularly with respect to decreased plasmenyl glycerophosphoethanolamine (PE) and increased plasmanyl glycerophosphocholine (PC) species, have previously been correlated with the onset and progression of several diseases,<sup>6,7)</sup> including cancer.<sup>8-11)</sup> Therefore, the development of methods to enable the identification, characterization and quantification of these biologically relevant molecules could lead to broader knowledge regarding the functional role of ether lipid metabolism in the pathogenesis of disease.

Recently, mass spectrometry (MS) and tandem mass spectrometry (MS/MS) methods have been established as attractive tools for rapid lipidome analysis from complex biological mixtures.<sup>12)</sup> However, the ability of mass spectrometry to identify, characterize and quantify the individual species present within a complex lipid mixture, even with high resolving power and accurate mass,<sup>13,14)</sup> can be limited due to the potential for many isobaric mass lipids to be present at the same *m*/*z* values. For example, protonated PE lipids containing an even number of total carbons within their fatty acyl or alkyl chains can have the same exact *m*/*z* values as the ammoniated adducts of glycerophosphatidic acid (PA) lipids containing two additional carbons and one double bond, as well as with odd chain length PC lipids containing three fewer carbons (*e.g.*,  $[PE_{(32:0)} + H]^+ = [PA_{(34:1)} + NH_4]^+$ [PC(29 : 0) +H] + ), while protonated glycerophosphoserine (PS) lipids can overlap in exact *m*/*z* with the ammoniated adducts of glycerophosphoglycerol (PG) lipids containing two additional double bonds  $(e.g. [PS_{(36:0)} + H]^+ = [PG_{(36:2)} +$ NH4] + ). Furthermore, plasmenyl-ether containing lipids are observed at identical *m*/*z* values to plasmanyl-ether containing lipids containing the same headgroup when both species contain the same total number (but different sites) of unsaturation (e.g.,  $[PE_{(P-36:0)} + H]^+ = [PE_{(O-36:1)} + H]^+$ ). Typically, to differentiate between these species using mass spectrometry methods, MS/MS and -MS<sup>3</sup> has been required.<sup>15)</sup> However, these approaches are not always practical for the characterization of low abundance lipids, particularly when present within complex mixtures. Alternatively, ozone induced dissociation (OzID) has also been reported as a means of locating double bonds in fatty acid chains, and therefore distinguishing between an unsaturated alkyl and a saturated alkenyl. 16)

The differentiation of ether lipid species has also previously been achieved by taking advantage of the susceptibility of the alkenyl ether linkage of the plasmenyl lipids to acid hydrolysis compared to alkyl ether or acyl linked lipid species,<sup>17)</sup> with subsequent separation of the reaction products by HPLC. 18) Recently, we described the development and application of a method involving functional group selective chemical modification of PE and PS lipids within crude cellular lipid extracts using a 'fixed charge' sulfonium ion containing  $d_6$ -*S*,*S'*-dimethylthiobutanoylhydroxysuccinimide ester  $(d_6$ -DMBNHS) reagent, followed by mild formic acid hydrolysis of the plasmenyl ether containing lipids,

<sup>\*</sup>Correspondence to: Gavin E. Reid, *Chemistry Building, 578 S. Shaw Lane. Room 229, Michigan State University, East Lansing, Michigan MI48824, USA*, e-mail: reid@chemistry.msu.edu

where mass spectrometric analysis before and after the hydrolysis reaction was used to monitor for the disappearance of the plasmenyl ether lipids within the mixture.<sup>11)</sup> By eliminating the possibility of isobaric mass overlap of PE and PS lipids with the precursor ions of all other lipids in crude lipid extracts, and by differentiating the presence of plasmenyl lipids from isobaric mass plasmanyl lipids, and when combined with MS/MS and/or MS<sup>3</sup> for characterization of the individual 'molecular lipid' species that were present at each of the 'sum composition'<sup>19)</sup> lipid mass values observed in the high resolution mass spectra, this method enabled the unambiguous assignment and differential quantification of over 600 lipid species between a primary colorectal cancer (CRC) cell line, SW480, and its isogenic lymph node metastasized derivative, SW620.<sup>11)</sup> However, this approach requires the acquisition of two MS spectra, *i.e.*, prior to and following the acid hydrolysis step, thereby increasing instrument and data analysis time. Therefore, it would be beneficial to further develop this analysis strategy to remove the requirement for sample degradation (*i.e.*, acid hydrolysis) and duplicate analyses.

In 1946, Siggia and Edsberg described a simple method for labeling vinyl alkyl ether bonds with iodine and methanol, with quantification by titration. 20) The method was later adapted for the quantification of plasmenyl ether lipids by back titration<sup>21)</sup> and, later, potentiometry.<sup>22)</sup> Although this reaction results in specific labeling of plasmenyl lipids, which would displace these species from isobaric plasmanyl lipids present in a crude mixture, and would therefore allow identification and quantification of both species by the acquisition of a single mass spectrum when used in conjunction with an aminophospholipid labeling strategy, the chemistry has not yet been adapted for application in a mass spectrometric analysis workflow. Here, therefore, we have adapted the plasmenyl ether specific iodine and methanol derivatization method, in conjunction with the use of a novel <sup>13</sup> C1-labelled version of our *S*,*S*′-dimethylthiobutanoylhydroxysuccinimide ester reagent (*i.e.*, <sup>13</sup>C<sub>1</sub>-DMBNHS) for functional group selective derivatization of amine-containing lipids, to further improve the capabilities of our 'shotgun' high resolution/accurate mass spectrometry workflow for comprehensive lipidome analysis. Additionally, the positive ionization mode tandem mass spectrometry fragmentation behavior of the derivatized plasmenyl ether containing PC and PE lipids have been examined, to demonstrate the utility of this chemical derivatization strategy for improved molecular lipid characterization of plasmenyl ether lipids.

### **MATERIALS AND METHODS**

*Reagents*: SW480 cells were purchased from American Type Culture Collection (ATCC) (Manassas, VA). Synthetic lipid standards were from Avanti Polar Lipids, Inc. (Alabaster, AL). RPMI 1640 medium, penicillin and streptomycin antibiotic mix and 0.25% Trypsin-EDTA were obtained from Invitrogen (Carlsbad, CA). LC grade water, methanol  $(CH<sub>3</sub>OH)$ , chloroform  $(CHCl<sub>3</sub>)$  and ACS grade isopropanol (IPA) were purchased from Macron Chemicals (Center Valley, PA). Iodine, *N*,*N*-dimethylformamide (DMF) and triethylamine (TEA) were from Jade Scientific (Westland, MI). Dichloromethane (DCM) was from Mallinckrodt Chemicals (Phillipsburg, NJ, USA). Acetonitrile (CH<sub>3</sub>CN) was purchased from EMD Chemicals (San Diego, CA, USA). Ammonium formate was obtained from Alfa Aesar (Ward Hill, MA). Ammonium bicarbonate was from J.T. Baker (Phillipsburg, NJ, USA). <sup>13</sup>C-iodomethane (99% <sup>13</sup>C) was obtained from Sigma Aldrich (St. Louis, MO, USA). <sup>1</sup>H NMR spectra were performed on a Varian Inova 500MHz instrument and recorded in parts per million (ppm) referenced to the solvent resonances  $(\delta)$ , with coupling constants  $(J)$  in hertz (Hz).

*Synthesis of <sup>13</sup> C1-S,S′-dimethylthiobutanoylhydroxysuccin imide ester ( 13 C1-DMBNHS)*: Methylthiobutyric hydroxysuccinimide ester (0.231 g, 1mmol) prepared as described previously,  $23$  and  $13$ C-iodomethane (0.71 g, 5 mmol) were dissolved in 2 mL of CH<sub>3</sub>CN followed by stirring in the dark at room temperature for 2 days. The resulting solution was then concentrated under reduced pressure. The resultant yellow solid was washed with 10mL of DCM then dried *in vacuo* to give 0.28 g (76%) of product as yellow crystals. The product was stored in the dark until further use. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>CN): δ 2.67, 2.97 (d, 3H, *J*=146.0), 2.77 (s, 4H), 2.82, 2.83 (d, 3H, *J*=4), 2.85 (t, 2H, *J*=7.0), 3.31 (m, 2H,  ${}^{3}J_{\text{C-H}} = 3.0, J_{\text{H-H}} = 7.5$ ).

*Cell culture*: SW480 cells were routinely cultured in RPMI1640 medium supplemented with 10% FBS, 100unit/ mL penicillin and  $100 \mu g/mL$  streptomycin at 37°C and 5% CO<sub>2</sub> atmosphere. Approximately  $2\times10^6$  cells were seeded into  $75 \text{ cm}^2$  culture flask containing  $10 \text{ mL}$  of the culture medium and cultured until cell density reached 80% confluence. The cells were washed three times with PBS and lifted off the culture plates with 0.25% Trypsin-EDTA. Cell suspensions were centrifuged at 1000 rpm and the cell pellets were washed once with PBS prior to lipid extraction.

*Lipid extraction*: Extraction of lipids from 2×10<sup>7</sup> SW480 cells was performed using a modified Folch method, as previously described.<sup>11,24,25)</sup> Stock solutions were prepared by dissolving the crude lipid extracts in  $600 \mu L$  of 4:2:1 IPA/ CH<sub>3</sub>OH/CHCl<sub>3</sub>. Lipid extracts were stored in 2mL glass vials with PTFE lined caps (Fisher Scientific, Fairlawn, NJ) at −80°C prior to further analysis.

*Derivatization of plasmenyl vinyl ether bonds with iodine and methanol*: 10µL each of 100µM lipid standards  $(PE_{(P-18:0/22:6)}, PC_{(P-18:0/22:6)}, PE_{(14:0/14:0)}, PE_{(18:0/22:6)}, PC_{(14:0/23:6)}$  $_{14:0}$ , PC<sub>(18:1/18:1</sub>), PC<sub>(18:2/18:2)</sub>, TG<sub>(14:0/16:1/14:0)</sub>, TG<sub>(16:0/16:0/18:1)</sub>,  $TG_{(18:1/16:0/18:1)}$  and  $TG_{(18:0/18:0/18:1)}$  were dried under a stream of nitrogen then redissolved in 60 $\mu$ L ice cold 2:1 CHCl<sub>3</sub>/CH<sub>3</sub>OH with 2mM ammonium bicarbonate and 0.167mM iodine (*i.e.*, a 5 fold molar excess with respect to the total plasmenyl lipid concentration). For cell extract reactions, 5  $\mu$ L of the stock SW480 lipid extract and 10  $\mu$ L each of 10  $\mu$ M PC<sub>(14:0/14:0)</sub> and PE<sub>(14:0/14:0)</sub> were combined then dried under a stream of nitrogen, then redissolved in 60  $\mu$ L ice cold  $2:1$  CHCl<sub>3</sub>/CH<sub>3</sub>OH with  $2 \text{ mM}$  ammonium bicarbonate and 1.33mM iodine (estimated to be a 10 fold molar excess with respect to the total plasmenyl lipid concentration). The solutions were reacted in an ice bath for 5 min and dried under a stream of nitrogen. The resulting products were then re-dissolved in 200  $\mu$ L 4:2:1 IPA/CH<sub>2</sub>OH/CHCl<sub>2</sub> containing 20mM ammonium formate for immediate analysis by MS.

*Derivatization of aminophospholipids with* <sup>13</sup>C<sub>1</sub>-S,S<sup>'</sup>*dimethylthiobutanoylhydroxysuccinimide ester ( 13 C1- DMBNHS*):  $5 \mu L$  of the stock SW480 lipid extract and  $10 \mu L$ 



Fig. 1. Positive ionization mode ESI high-resolution mass spectrometric analysis of a mixture of PC, PE and TG synthetic lipid standards, including two plasmenyl ether containing PC and PE lipids (A) without derivatization and (B) after reaction with iodine and methanol. The insets to each panel show an expanded region (*m*/*z* 760–825) of the mass spectra containing the underivatized plasmenyl PC and PE lipids.

each of 10  $\mu$ M PC<sub>(14:0/14:0)</sub> and PE<sub>(14:0/14:0)</sub> were combined then dried under a stream of nitrogen, then redissolved in  $40 \mu L$  of 39:1.1 CHCl<sub>3</sub>/0.00625 M TEA and vortexed for 30 s.  $1 \mu$ L of 0.00625 M <sup>13</sup>C<sub>1</sub>-DMBNHS in DMF was then added to the lipid mixture and vortexed for 30 min. The reactions were quenched by drying under a stream of nitrogen then re-dissolved in 200  $\mu$ L 4:2:1 IPA/CH<sub>2</sub>OH/CHCl<sub>2</sub> containing 20mM ammonium formate for immediate analysis by MS, or were subjected to iodine/CH<sub>3</sub>OH derivatization of vinyl ether bonds prior to MS analysis, as described above.

*Mass spectrometry analysis:* Samples were loaded into a Whatman multichem 96-well plate (Sigma Aldrich, St. Louis, MO) and sealed with Teflon Ultra Thin Sealing Tape (Analytical Sales and Services, Prompton Plains, NJ). The samples were then introduced into a high resolution/accurate mass Thermo Scientific model LTQ Orbitrap Velos mass spectrometer equipped with a dual pressure ion trap and an HCD multipole collision cell (San Jose, CA) with an inlet temperature of 100°C and S-Lens value of 50% using an Advion Triversa Nanomate nano-electrospray ionization (nESI) source (Advion Ithaca, NY) with a spray voltage of 1.4 kV and a gas pressure of 0.3psi. Mass spectra were acquired in positive ionization mode using the FT analyzer operating at 100,000 resolving power and were signal averaged for 2 min. External calibration of the instrument was performed using the standard Thermo LTQ calibration mixture. All product ion MS/MS experiments were acquired in positive ionization mode on monoisotopically isolated precursor ions with default activation times using the FT analyzer (100,000 resolving power) for 30 s. Higher-energy Collision induced Dissociation (HCD-MS/MS) product ion spectra were acquired with a low *m*/*z* limit of 150, while conventional ion trap Collision Induced Dissociation (CID)-  $MS/MS$  and - $MS<sup>3</sup>$  product ion spectra were acquired with a *q*-value of 0.17.

# **RESULTS**

## **Selective derivatization and high-resolution/accurate mass spectrometry of plasmenyl lipids**

To demonstrate the selectivity and completeness of the iodine and methanol reaction conditions described above for the derivatization of plasmenyl ether lipids, the positive ion mode high-resolution mass spectra acquired from a mixture of synthetic lipid standards  $(PE_{(18:0/22:6)}$ *m*/*z* 792.5494, PC(18 : 1/18 : 1) , *m*/*z* 786.5963, PC(18 : 2/18 : 2) , *m*/*z* 782.5652, TG(14 : 0/16 : 1/14 : 0) , *m*/*z* 766.6880, TG(16 : 0/16 : 0/18 : 1) , *m*/*z* 850.7812, TG<sub>(18:1/16:0/18:1)</sub>, *m/z* 876.7966, and TG<sub>(18:0/18:0/18:1)</sub>, *m*/*z* 906.8432), including two plasmenyl ether glycerophospholipids (PE<sub>(P-18:0/22:6)</sub>, *m/z* 776.5551 and PC<sub>(P-18:0/22:6)</sub>, *m/z* 818.6014), before and after reaction with iodine/CH<sub>3</sub>OH, are shown in Figs. 1A and 1B, respectively. From these spectra, it can be seen that complete and selective reaction of the plasmenyl ether lipids within the mixture had occurred, with new ions corresponding to the derivatized plasmenyl PE and PC lipids appearing at *m*/*z* 934.4768 (*i.e.*, the addition of 157.9217Da) and *m*/*z* 976.5235 (*i.e.*, the addition of 157.92221Da), respectively, consistent with the addition of I+OCH3 (calculated mass 157.9229Da). A low abundance ion at *m*/*z* 902.4502 corresponding to the in-source loss of methanol from the  $[PE_{(P-18:0/22:6)}+H+H+OCH_3]^+$  ion was also observed. Importantly, despite the presence of numerous mono- and poly-unsaturated fatty acids within the other lipids in the standard mixture, no reaction of these lipids was



Fig. 2. Positive ionization mode ESI high-resolution mass spectrometric analysis of a crude lipid extract from the SW480 human adenocarcinoma cell line (A) without derivatization, (B) after reaction with the amine-specific derivatization reagent,  ${}^{13}C_1$ -DMBNHS, and (C) after reaction with  $^{13}C_1$ -DMBNHS followed by reaction with iodine and methanol. The boxed regions in panels B and C show the major regions of the spectra in which the derivatized aminophospholipids (+131.0486Da) and the derivatized plasmenyl lipids (+157.9229Da) appear, following their respective derivatization reactions.

observed. Furthermore, no change in the relative sensitivity was observed for any of the underivatized or derivatized lipids following the reaction. Note that the reaction was performed at 0°C to ensure that the reaction occurred exclusively with the plasmenyl lipid species. Furthermore, 2mM ammonium bicarbonate was added to the reaction solution as a buffer to avoid the possibility of acid hydrolysis of the plasmenyl lipids due to the formation of hydriodic acid during the reaction.

The selective iodine/CH<sub>3</sub>OH plasmalogen derivatization method was then applied to a crude lipid extract from a colon adenocarcinoma cell line, SW480, that had first been subjected to functional group selective derivatization of the PE and PS aminophospholipids within the mixture using the novel <sup>13</sup>C<sub>1</sub>-S,S'-dimethylthiobutanoylhydroxysuccinimide ester  $(^{13}C_1$ -DMBNHS) reagent, similar to that recently described.<sup>11)</sup> The positive ion mode high-resolution mass spectrum of the crude underivatized extract is shown in Fig. 2A, while the spectra obtained following reaction with the  ${}^{13}C_1$ -DMBNHS reagent is shown in Fig. 2B. From a comparison of these spectra, numerous ions in Fig. 2B are observed to appear at *m*/*z* values 131.0486Da higher than that of the underivatized spectra, indicating the presence of  $^{13}C_1$ -DMBNHS derivatized PE and PS lipids. For example,

*m*/*z* 767.5053 in Fig. 2B corresponds to the derivatized form of the PE(28 : 0) internal standard (*m*/*z* 636.4570) from Fig. 2A, while *m*/*z* 833.5870 in Fig. 2B corresponds to the derivatized form of *m*/*z* 702.5403 from Fig. 2A, indicating the presence of a  $\text{PE}_{(\text{P-34:1})}$  and/or  $\text{PE}_{(\text{O-34:2})}$  lipid within the extract.

Upon further treatment of the  ${}^{13}C_1$ -DMBNHS labeled lipid extract with methanol and iodine, numerous lipids appeared at *m*/*z* values shifted by 157.9229Da, indicating the presence of plasmenyl lipids *via* the addition of I+OCH<sub>3</sub>. For example, *m*/*z* 833.5870 in Fig. 2B had largely shifted to  $m/z$  991.5090 (Fig. 2C) indicating the presence of  $PE_{(P-34:1)}$ while the residual ion abundance at *m*/*z* 833.5870 indicated the presence of  $PE_{(O-34:2)}$ . Consistent with the results from the standard lipid mixture, no change in abundances were observed for any of the other diacyl or alkyl ether containing ions in the crude lipid extract (*e.g.*, *m*/*z* 875.5971 corresponding to the <sup>13</sup>C<sub>1</sub>-DMBNHS derivatized diacyl PE<sub>(36:2)</sub>, and *m*/*z* 746.6017 corresponding to the protonated plasmanyl PC $_{(O-34:1)}$ ). Interestingly, no in-source fragmentation corresponding to the loss of methanol from the  ${}^{13}C_1$ -DMBNHS derivatized PE plasmenyl lipids derivatized with iodine and methanol were observed, suggestive of an improved stability of the DMBNHS derivatized lipid ions. Notably, from an analysis of the mass spectra in Fig. 2C using the Lipid



Scheme 1. Proposed CID-MS/MS fragmentation mechanisms for the plasmenyl ether containing  $PC_{(P-18:0/22:6)}$  lipid, prior to and following reaction with iodine and methanol. The *m*/*z* values shown correspond to the calculated masses of the various product ions.



Fig. 3. Positive ionization mode ESI high-resolution HCD-MS/MS analysis of the synthetic lipid standard PC<sub>(P-18:0/22:6)</sub> (A) without derivatization and (B) after reaction with iodine and methanol. The horizontal arrows in panel B indicate the fragmentation pathways that were observed upon performing ion trap multistage CID-MS*<sup>n</sup>* of the derivatized PC precursor ion.

Mass Spectrum Analysis (LIMSA) v.1.0 software linear fit isotope correction algorithm<sup>26)</sup> (data not shown), a similar number of lipids were identified compared to our previous report<sup>11)</sup> indicating that this approach could be successfully

employed for the analysis of crude cellular lipid extracts. The results from the application of this improved method, for the identification and quantification of differences in lipid abundances between various colon cancer cell lines,



Fig. 4. Positive ionization mode ESI high-resolution HCD-MS/MS analysis of the synthetic lipid standard  $PE_{(P-18:0/22:6)}$  (A) without derivatization, (B) after reaction with iodine and methanol, (C) after derivatization with  ${}^{13}C_1$ -DMBNHS, and (D) after derivatization with  ${}^{13}C_1$ -DMBNHS followed by reaction with iodine and methanol. The horizontal arrows in panels B–D indicate the fragmentation pathways that were observed upon performing ion trap multistage CID-MS<sup>n</sup> of the derivatized PE precursor ions.

will be reported elsewhere.

## **MS/MS structural characterization of derivatized plasmenyl PC lipids**

CID-MS/MS of protonated plasmenyl ether PC lipids in positive ionization mode results in the formation of a dominant product ion fragment at *m*/*z* 184.0739, corresponding to the phosphocholine headgroup (Scheme 1, pathway *a*), while the product ion corresponding to characteristic loss of the plasmenyl chain as a neutral alkenyl alcohol (note that an analogous loss is not observed for plasmanyl ether containing PC lipids) (Scheme 1, pathway *b*), 27) is observed only at very low abundance. An example is shown in Fig. 3A for HCD-MS/MS of the  $PC_{(P-18:0/22:6)}$  lipid from Fig. 1A. In negative ionization mode, CID-MS/MS of the acetate or formate adducts of plasmenyl PC lipids results in initial loss of methyl acetate or methyl formate, followed by the formation of a low abundance product ion corresponding to neutral loss of the 2-sn fatty acid. However, as this dissociation behavior does not allow the differentiation of plasmenyl or plasmanyl ether chains, further dissociation by MS<sup>3</sup> is typically required. 15) Thus, the low abundance of the characteristic product ion in positive ion mode MS/MS, and the necessity for  $MS<sup>3</sup>$  in negative ion mode, can severely limit the applicability of these methods for the analysis of very low abundant plasmalogen PC lipids that may be present within a complex crude lipid extract.

In contrast, positive ion mode HCD-MS/MS of the iodine/CH3OH derivatized plasmenyl PC lipid (*i.e.*, [PC(P-18 : 0/22 : 6) +I+OCH3+H] <sup>+</sup> (*m*/*z* 976.5279) from Fig. 1B) (Fig. 3B), resulted in the formation of a dominant product ion corresponding to characteristic cleavage of the derivatized plasmenyl ether chain with neutral loss of a characteristic R<sub>1</sub>CICHOCH<sub>3</sub> alkene (m/z 568.3392), that directly



Scheme 2. Proposed CID-MS/MS fragmentation mechanisms for the plasmenyl ether containing  $PE_{(P-18:0/22:6)}$  lipid, prior to and following reaction with iodine and methanol. The *m*/*z* values shown correspond to the calculated masses of the various product ions.

enabled assignment of the molecular lipid identity (*i.e.*,  $PC_{(P-18:0/22:6)}$  rather than  $PC_{(O-18:1/22:6)}$ , as well as an abundant product ion at *m*/*z* 944.5017 corresponding to the loss of methanol, both of which also underwent further dissociation to yield the abundant PC headgroup specific ion at *m*/*z* 184.0734. Mechanistic proposals for formation of each of these product ions, supported by the high resolution/ accurate mass performance of the Orbitrap mass spectrometer, and data acquired *via* ion trap multistage CID-MS*<sup>n</sup>* experiments (the sequential fragmentation pathways observed from these experiments are shown as dotted lines in the figures), are shown in Scheme 1, pathways *c* and *d*, respectively. Note that the low abundance ion at *m*/*z* 694.2357 in Fig. 3B, corresponding to loss of the 1-sn alkenyl chain as a neutral R<sup>'</sup>CHCHOCH<sub>3</sub> alkene *via* the pathway proposed in Scheme 1, pathway *e*, is likely to be observed only for C22:6 fatty acyl chain containing plasmenyl lipids, due to the specific sites of unsaturation located within this particular acyl chain.

### **MS/MS structural characterization of derivatized plasmenyl PE lipids**

A comparison of the HCD-MS/MS spectra acquired from the protonated, iodine/ $CH_3OH$  derivatized, <sup>13</sup>C<sub>1</sub>-DMBNHS derivatized, and sequentially  $^{13}C_1$ -DMBNHS and iodine/  $CH<sub>3</sub>OH$  derivatized plasmenyl ether  $PE<sub>(P-18: 0/22:6)</sub>$  lipid precursor ions, are shown in Figs. 4A–D, respectively. The abundant product ions at *m*/*z* 385.2738 and *m*/*z* 392.2924 observed upon dissociation of the underivatized protonated plasmenyl PE lipid from Fig. 1A (Fig. 4A), corresponding to loss of the 2-sn acyl and 1-sn alkenyl chains, respectively, directly enable assignment of the molecular lipid identity. These products are consistent with those previously reported by Zemski Berry and Murphy, who also provided a sound mechanistic rationale for their formation<sup>28)</sup> (Scheme 2, pathways *a* and *b*).

In contrast, the primary fragmentation pathway for the iodine/CH<sub>3</sub>OH derivatized plasmenyl ether  $PE_{(P-18:0/22:6)}$ lipid from Fig. 1B (Fig. 4B) corresponded to the loss of methanol (*m*/*z* 902.4546) (Scheme 2, pathway *c*). A lower abundance product ion formed *via* the neutral loss of the



Scheme 3. Proposed CID-MS/MS fragmentation mechanisms for the <sup>13</sup>C<sub>1</sub>-DMBNHS derivatized plasmenyl ether containing PE<sub>(P-18:0/22:6)</sub> lipid, prior to and following reaction with iodine and methanol. The *m*/*z* values shown correspond to the calculated masses of the various product ions.

characteristic R1 ′CICHOCH3 alkene (*m*/*z* 526.2923) (Scheme 2, pathway *d*) was also observed, analogous to that proposed in Scheme 1, pathway  $c$  for the iodine/CH<sub>3</sub>OH derivatized plasmenyl PC lipid, from which the molecular lipid identity could be directly assigned (*i.e.*, PE<sub>(P-18:0/22:6)</sub> rather than PE(O-18 : 1/22 : 6) ). Further dissociation of the *m*/*z* 902.4546 product ion during HCD-MS/MS (or by CID-MS<sup>3</sup>) resulted in the formation of product ions similar to those observed for the underivatized PE lipid (*e.g.*, compare Scheme 2, pathways *e* and *f* for the formation of *m*/*z* 385.2736 and *m*/*z* 518.1885, with Scheme 2, pathways *b* and *a*, respectively). Several other minor products were also observed, including *m*/*z* 508.2817, formed *via* the pathway proposed in Scheme 2 pathway *g*, as well as *m*/*z* 884.4430, *m*/*z* 774.5420 and *m*/*z* 761.4356 formed *via* the losses of H<sub>2</sub>O, HI and the phosphoethanolamine head group, respectively.

Derivatization of the plasmenyl PE lipid with the  ${}^{13}C_1$ -DMBNHS reagent, resulting in the introduction of a 'fixed charge' sulfonium ion, significantly altered the gas-phase fragmentation behavior (Fig. 4C). Here, the dominant initial product ion at *m*/*z* 844.5860 was formed *via* the neutral loss of 63.0024 Da (*i.e.*, <sup>13</sup>C<sub>1</sub>-dimethylsulfide), resulting in a 5 membered protonated iminohydrofuran ring on the headgroup (Scheme 3, pathway *a*). This was followed by further dissociation similar to that seen for the plasmenyl PC lipid in Fig. 3A, yielding a dominant product ion corresponding to the derivatized phosphoethanolamine headgroup at *m*/*z* 210.0532, its complementary 209Da neutral loss product at *m*/*z* 635.5407 formed *via* intra-complex proton transfer (Scheme 3, pathway *b*), as well as a low abundance product ion at *m*/*z* 576.3090 formed *via* characteristic loss of the plasmenyl chain as a neutral alkenyl alcohol (Scheme 3, pathway *c*) from which direct assignment of the molecular lipid identity (*i.e.*,  $PE_{(P-18:0/22:6)}$  rather than  $PE_{(O-18:1/22:6)}$ ) could be achieved, albeit with poor detection sensitivity.

Finally, the spectrum acquired upon HCD-MS/MS of the sequentially  ${}^{13}C_1$ -DMBNHS and iodine/CH<sub>3</sub>OH derivatized plasmenyl ether  $PE_{(P-18:0/22:6)}$  lipid is shown in Fig. 4D. Similar to the plasmenyl PE lipid derivatized only with <sup>13</sup>C<sub>1</sub>-DBMNHS, the dominant neutral loss of <sup>13</sup>C<sub>1</sub>dimethylsulfide (*m*/*z* 1002.5069) was observed as the primary fragmentation pathway (Scheme 3, pathway *d*). Then, further dissociation of this initial product ion was found to be essentially identical to that observed from the iodine/ CH3OH derivatized plasmenyl PC lipid in Fig. 3B, with the major product ion formed *via* neutral loss of the characteristic R<sub>1</sub>CICHOCH<sub>3</sub> alkene (*m/z* 594.3185), that directly enabled assignment of the molecular lipid identity (*i.e.*,  $PC_{(P-18:0/22:6)}$  rather than  $PC_{(O-18:1/22:6)}$  (Scheme 3, pathway *e*), as well as an abundant product ion corresponding to the loss of methanol (*m*/*z* 970.4906) that also underwent further dissociation to yield the abundant derivatized PE headgroup specific ion at *m*/*z* 210.0527 (Scheme 3, pathway *f*) and its low abundance complementary 209Da neutral loss product at *m*/*z* 793.4618. Interestingly, the minor product ion at *m*/*z* 720.2148, corresponding to loss of the 1-sn alkenyl chain as a neutral R<sup>'</sup>CHCHOCH<sub>3</sub> alkene *via* a pathway the same as that proposed in Scheme 1, pathway *e* for the iodine/CH<sub>2</sub>OH derivatized plasmenyl PC lipid, was not observed for the plasmenyl PE lipid that had only been derivatized with iodine/CH<sub>3</sub>OH (*i.e.*, no <sup>13</sup>C<sub>1</sub>-DMBNHS), suggesting that this reaction pathway is only energetically competitive under 'non-mobile' protonation conditions.

### **CONCLUSION**

The results shown herein indicate that sequential functional group specific lipid derivatization reactions can be successfully developed and applied to fully resolve, identify the presence of, and characterize the molecular lipid compositions of plasmenyl ether containing lipid species from within crude complex lipid extracts based on the characteristic mass shifts observed upon 'shotgun' high resolution/accurate mass spectrometry, and/or the characteristic product ions formed upon tandem mass spectrometry analysis of their mass selected precursor ions. The reactions are simple, fast, and proceed to completion without non-specific modification of other lipids that may be present within a given mixture. Coupled with its ability to significantly reduce or eliminate the need for chromatographic fractionation or additional lipid extraction steps prior to analysis, this approach represents an attractive strategy for use in future studies aimed at developing an improved understanding of the structures and functions of plasmenyl and plasmanyl ether lipids in health and disease.

#### **Acknowledgement**

Support for this work was provided by funding from the National Institutes of Health to GER (GM103508).

## **REFERENCES**

- 1) R. C. Murphy. [Free-radical-induced](http://dx.doi.org/10.1021/tx000250t) oxidation of arachidonoyl plasmalogen [phospholipids:](http://dx.doi.org/10.1021/tx000250t) Antioxidant mechanism and precursor pathway for bioactive [eicosanoids.](http://dx.doi.org/10.1021/tx000250t) *Chem. Res. Toxicol.* 14: [463–472,](http://dx.doi.org/10.1021/tx000250t) 2001.
- 2) P. V. Escribá, J. M. [González-Ros,](http://dx.doi.org/10.1111/j.1582-4934.2008.00281.x) F. M. Goñi, P. K. Kinnunen, L. Vigh, L. [Sánchez-Magraner,](http://dx.doi.org/10.1111/j.1582-4934.2008.00281.x) A. M. Fernández, X. Busquets, I. Horváth, G. [Barceló-Coblijn.](http://dx.doi.org/10.1111/j.1582-4934.2008.00281.x) Membranes: A meeting point for lipids, proteins and [therapies.](http://dx.doi.org/10.1111/j.1582-4934.2008.00281.x) *J. Cell. Mol. Med.* 12: 829–875, [2008.](http://dx.doi.org/10.1111/j.1582-4934.2008.00281.x)
- 3) G. van Meer, D. R. Voelker, G. W. Feigenson. [Membrane](http://dx.doi.org/10.1038/nrm2330) lipids: Where they are and how they [behave.](http://dx.doi.org/10.1038/nrm2330) *Nat. Rev. Mol. Cell Biol.* 9: [112–124,](http://dx.doi.org/10.1038/nrm2330) 2008.
- 4) P. E. Glaser, R. W. Gross. [Plasmenylethanolamine](http://dx.doi.org/10.1021/bi00185a019) facilitates rapid membrane fusion: A [stopped-flow](http://dx.doi.org/10.1021/bi00185a019) kinetic investigation correlating the propensity of a major plasma membrane [constituent](http://dx.doi.org/10.1021/bi00185a019) to adopt an HII phase with its ability to promote [membrane](http://dx.doi.org/10.1021/bi00185a019) fusion. *[Biochemistry](http://dx.doi.org/10.1021/bi00185a019)* 33: 5805–5812, 1994.
- 5) T. P. Thai, C. Rodemer, A. Jauch, A. [Hunziker,](http://dx.doi.org/10.1093/hmg/10.2.127) A. Moser, K. Gorgas, W. W. Just. Impaired [membrane](http://dx.doi.org/10.1093/hmg/10.2.127) traffic in defective ether lipid [biosynthesis.](http://dx.doi.org/10.1093/hmg/10.2.127) *Hum. Mol. Genet.* 10: 127–136, 2001.
- 6) N. E. Braverman, A. B. Moser. Functions of [plasmalogen](http://dx.doi.org/10.1016/j.bbadis.2012.05.008) lipids in health and disease. *Biochim. Biophys. Acta* 1822: [1442–1452,](http://dx.doi.org/10.1016/j.bbadis.2012.05.008) [2012.](http://dx.doi.org/10.1016/j.bbadis.2012.05.008)
- 7) T. F. da Silva, V. F. Sousa, A. R. [Malheiro,](http://dx.doi.org/10.1016/j.bbadis.2012.05.014) P. Brites. The importance of [ether-phospholipids:](http://dx.doi.org/10.1016/j.bbadis.2012.05.014) A view from the perspective of mouse models. *Biochim. Biophys. Acta* 1822: [1501–1508,](http://dx.doi.org/10.1016/j.bbadis.2012.05.014) 2012.
- 8) R. E. Smith, P. Lespi, M. Di Luca, C. [Bustos,](http://dx.doi.org/10.1007/s11745-007-3133-6) F. A. Marra, M. J. T. de Alaniz, C. A. Marra. A reliable [biomarker](http://dx.doi.org/10.1007/s11745-007-3133-6) derived from [plasmalogens](http://dx.doi.org/10.1007/s11745-007-3133-6) to evaluate malignancy and metastatic capacity of human [cancers.](http://dx.doi.org/10.1007/s11745-007-3133-6) *Lipids* 43: 79–89, 2008.
- 9) T. E. [Merchant,](http://dx.doi.org/10.1007/BF00300208) J. N. Kasimos, P. W. de Graaf, B. D. Minsky, L. W. Gierke, T. Glonek. [Phospholipid](http://dx.doi.org/10.1007/BF00300208) profiles of human colon cancer using <sup>31</sup> P magnetic resonance [spectroscopy.](http://dx.doi.org/10.1007/BF00300208) *Int. J. Colorectal Dis.* 6: [121–126,](http://dx.doi.org/10.1007/BF00300208) 1991.
- 10) D. A. [Dueck,](http://dx.doi.org/10.1007/BF00227535) M. Chan, K. Tran, J. T. Wong, F. T. Jay, C. Littman, R. Stimpson, P. C. Choy. The [modulation](http://dx.doi.org/10.1007/BF00227535) of choline [phosphoglyceride](http://dx.doi.org/10.1007/BF00227535) metabolism in human colon cancer. *Mol. Cell. [Biochem.](http://dx.doi.org/10.1007/BF00227535)* 162: 97–103, 1996.
- 11) C. J. Fhaner, S. Liu, H. Ji, R. J. Simpson, G. E. Reid. [Comprehen](http://dx.doi.org/10.1021/ac302154g)sive lipidome profiling of isogenic primary and [metastatic](http://dx.doi.org/10.1021/ac302154g) colon [adenocarcinoma](http://dx.doi.org/10.1021/ac302154g) cell lines. *Anal. Chem.* 84: 8917–8926, 2012.
- 12) X. Han, K. Yang, R. W. Gross. [Multi-dimensional](http://dx.doi.org/10.1002/mas.20342) mass spec[trometry-based](http://dx.doi.org/10.1002/mas.20342) shotgun lipidomics and novel strategies for lipidomic analyses. *Mass [Spectrom.](http://dx.doi.org/10.1002/mas.20342) Rev.* 31: 134–178, 2012.
- 13) C. S. Ejsing, J. L. Sampaio, V. [Surendranath,](http://dx.doi.org/10.1073/pnas.0811700106) E. Duchoslav, K. Ekroos, R. W. Klemm, K. Simons, A. [Shevchenko.](http://dx.doi.org/10.1073/pnas.0811700106) Global analysis of the yeast lipidome by [quantitative](http://dx.doi.org/10.1073/pnas.0811700106) shotgun mass spectrometry. *Proc. Natl. Acad. Sci. U.S.A.* 106: [2136–2141,](http://dx.doi.org/10.1073/pnas.0811700106) 2009.
- 14) D. Schwudke, K. [Schuhmann,](http://dx.doi.org/10.1101/cshperspect.a004614) R. Herzog, S. R. Bornstein, A. [Shevchenko.](http://dx.doi.org/10.1101/cshperspect.a004614) Shotgun lipidomics on high resolution mass spec[trometers.](http://dx.doi.org/10.1101/cshperspect.a004614) *Cold Spring Harb. Perspect. Biol.* 3: a004614, 2011.
- 15) F. F. Hsu, J. Turk. [Differentiation](http://dx.doi.org/10.1016/j.jasms.2007.08.019) of 1-*O*-alk-1′-enyl-2-acyl and 1-*O*-alkyl-2-acyl [glycerophospholipids](http://dx.doi.org/10.1016/j.jasms.2007.08.019) by multiple-stage linear ion-trap mass [spectrometry](http://dx.doi.org/10.1016/j.jasms.2007.08.019) with electrospray ionization. *J. Am. Soc. Mass Spectrom.* 18: [2065–2073,](http://dx.doi.org/10.1016/j.jasms.2007.08.019) 2007.
- 16) J. M. Deeley, M. C. Thomas, R. J. W. [Truscott,](http://dx.doi.org/10.1021/ac802395d) T. W. Mitchell, S. J. Blanksby. [Identification](http://dx.doi.org/10.1021/ac802395d) of abundant alkyl ether glycero[phospholipids](http://dx.doi.org/10.1021/ac802395d) in the human lens by tandem mass spectrometry [techniques.](http://dx.doi.org/10.1021/ac802395d) *Anal. Chem.* 81: 1920–1930, 2009.
- 17) R. M. C. Dawson. A hydrolytic procedure for the identification and estimation of individual phospholipids in biological samples. *Biochem. J.* 75: 45–53, 1960.
- 18) E. J. Murphy, R. Stephens, M. [Jurkowitz-Alexander,](http://dx.doi.org/10.1007/BF02536090) L. A. Horrocks. Acidic hydrolysis of [plasmalogens](http://dx.doi.org/10.1007/BF02536090) followed by highperformance liquid [chromatography.](http://dx.doi.org/10.1007/BF02536090) *Lipids* 28: 565–568, 1993.
- 19) K. Ekroos. Lipidomics perspective: From molecular lipidomics to validated clinical diagnostics. In Lipidomics, Technologies and Applications. Wiley-VCH, Weinheim, Germany, 2012, Chapter 1.
- 20) S. Siggia, R. L. Edsberg. Iodometric [determination](http://dx.doi.org/10.1021/ac60020a026) of vinyl alkyl ethers. *Anal. Chem.* 20: [762–763,](http://dx.doi.org/10.1021/ac60020a026) 1948.
- 21) M. M. Rapport, B. Lerner. The structure of [plasmalogens.](http://dx.doi.org/10.1016/0006-3002(59)90119-2) *Biochim. Biophys. Acta* 33: [319–325,](http://dx.doi.org/10.1016/0006-3002(59)90119-2) 1959.
- 22) W. T. Norton. [Potentiometric](http://dx.doi.org/10.1016/0006-3002(60)91250-6) iodometric determination of plasmalogen. *Biochim. Biophys. Acta* 38: [340–342,](http://dx.doi.org/10.1016/0006-3002(60)91250-6) 1960.
- 23) X. Zhou, Y. Lu, W. Wang, B. [Borhan,](http://dx.doi.org/10.1016/j.jasms.2010.03.047) G. E. Reid. 'Fixed charge' chemical [derivatization](http://dx.doi.org/10.1016/j.jasms.2010.03.047) and data dependant multistage tandem mass [spectrometry](http://dx.doi.org/10.1016/j.jasms.2010.03.047) for mapping protein surface residue accessibility. *J. Am. Soc. Mass Spectrom.* 21: [1339–1351,](http://dx.doi.org/10.1016/j.jasms.2010.03.047) 2010.
- 24) J. Folch, M. Lees, G. H. Sloane Stanley. A simple method for the

isolation and purification of total lipides from animal tissues. *J. Biol. Chem.* 226: 497–509, 1957.

- 25) T. A. Lydic, J. V. Busik, W. J. [Esselman,](http://dx.doi.org/10.1007/s00216-009-2717-9) G. E. Reid. Complementary [precursor](http://dx.doi.org/10.1007/s00216-009-2717-9) ion and neutral loss scan mode tandem mass spectrometry for the analysis of [glycerophosphatidylethanol](http://dx.doi.org/10.1007/s00216-009-2717-9)amine lipids from whole rat retina. *Anal. [Bioanal.](http://dx.doi.org/10.1007/s00216-009-2717-9) Chem.* 394: [267–275,](http://dx.doi.org/10.1007/s00216-009-2717-9) 2009.
- 26) P. Haimi, A. Uphoff, M. [Hermansson,](http://dx.doi.org/10.1021/ac061390w) P. Somerharju. Software tools for analysis of mass [spectrometric](http://dx.doi.org/10.1021/ac061390w) lipidome data. *Anal.*

*Chem.* 78: [8324–8331,](http://dx.doi.org/10.1021/ac061390w) 2006.

- 27) S. P. Hui, H. Chiba, T. Kurosawa. Liquid [chromatography-mass](http://dx.doi.org/10.1007/s00216-011-4921-7) spectrometric [determination](http://dx.doi.org/10.1007/s00216-011-4921-7) of plasmalogens in human plasma. *Anal. Bioanal. Chem.* 400: [1923–1931,](http://dx.doi.org/10.1007/s00216-011-4921-7) 2011.
- 28) K. A. Zemski Berry, R. C. Murphy. [Electrospray](http://dx.doi.org/10.1016/j.jasms.2004.07.009) ionization tandem mass spectrometry of [glycerophosphoethanolamine](http://dx.doi.org/10.1016/j.jasms.2004.07.009) plasmalogen [phospholipids.](http://dx.doi.org/10.1016/j.jasms.2004.07.009) *J. Am. Soc. Mass Spectrom.* 15: [1499–1508,](http://dx.doi.org/10.1016/j.jasms.2004.07.009) 2004.